November 2, 2021
Plasmaconcept AG, headquartered in Köln, Germany, has chosen Circles to conduct a multi-center, post-market surveillance study on its IM.P.A.C.T. platform for autologous cell therapies.
Working with multiple independent European customer sites, and under ethics committee approval, Plasmaconcept AG will aggregate longitudinal outcomes data from real-world patients suffering from tendinopathy and osteoarthritis of various joints. Patient compliance in this real-world study will be a key factor, so Plasmaconcept AG will be taking steps to ensure:
Complementing this strong patient follow-up regimen are key clinical criteria, such as the specific dosages of erythrocytes, leukocytes and platelets chosen for each patient/indication. Such data will require less than a minute of work per site per patient but will support meaningful correlations which advance working knowledge on autologous cell therapy dosages.
Plasmaconcept AG anticipates ethics committee approval before close of 2021 and will be launching its Circle in early 2022.
If you would like more information about Plasmaconcept AG, its IM.P.A.C.T. device, or its post-market surveillance Circles, contact us here.
November 2, 2021
Plasmaconcept AG, headquartered in Köln, Germany, has chosen Circles to conduct a multi-center, post-market surveillance study on its IM.P.A.C.T. platform for autologous cell therapies.
Working with multiple independent European customer sites, and under ethics committee approval, Plasmaconcept AG will aggregate longitudinal outcomes data from real-world patients suffering from tendinopathy and osteoarthritis of various joints. Patient compliance in this real-world study will be a key factor, so Plasmaconcept AG will be taking steps to ensure:
Complementing this strong patient follow-up regimen are key clinical criteria, such as the specific dosages of erythrocytes, leukocytes and platelets chosen for each patient/indication. Such data will require less than a minute of work per site per patient but will support meaningful correlations which advance working knowledge on autologous cell therapy dosages.
Plasmaconcept AG anticipates ethics committee approval before close of 2021 and will be launching its Circle in early 2022.
If you would like more information about Plasmaconcept AG, its IM.P.A.C.T. device, or its post-market surveillance Circles, contact us here.